Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02235272 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation
A Phase 3 study of Pain and Inflammation, sponsored by Xigen.
- Completed
- Registry status
- Phase 3
- Development phase
- 339
- Enrollment target
- 1
- Study location
NCT02235272 is a Phase 3 study of Pain and Inflammation that has completed, run by Xigen. The registered enrollment target is 339 participants, above the 303-participant average among 374 other Pain trials with a reported enrollment target (12% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02235272, a Phase 3 study of Pain and Inflammation, has completed, sponsored by Xigen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 339 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the clinical efficacy and safety of XG-102 (900µg) compared to vehicle in the treatment of subjects with inflammation and pain following cataract surgery.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG XG-102
Study Locations (1)
California
- - Garden Grove
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 339 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02235272
The ClinicalTrials.gov registry entry for NCT02235272 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 339 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 303-participant average among 374 other Pain trials with a reported enrollment target (12% higher). The listed sponsor is Xigen, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02235272 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02235272 about?
NCT02235272 is a clinical study titled "Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation". The purpose of this study is to evaluate the clinical efficacy and safety of XG-102 (900µg) compared to vehicle in the treatment of subjects with inflammation and pain following cataract surgery.
What is the current status of trial NCT02235272?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 339 participants. The study started on 2014-09. Estimated completion is 2015-12.
What conditions does trial NCT02235272 study?
This clinical trial studies the following conditions: Pain, Inflammation, Cataract.
What interventions are being tested in trial NCT02235272?
The interventions under investigation include: Placebo (DRUG), XG-102 (DRUG).
Who is sponsoring clinical trial NCT02235272?
This trial is sponsored by Xigen, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02235272 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures: A Pragmatic, Randomized Controlled Trial
RECRUITING · Phase 3
-
Opioid-Free Orthopaedics
RECRUITING · Phase 3
-
Suzetrigine in Total Hip Arthroplasty
RECRUITING · Phase 3
-
Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits
RECRUITING · Phase 3
-
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment
RECRUITING · Phase 3
-
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.